Bristol-Myers Squibb Company Profile (NYSE:BMY)

About Bristol-Myers Squibb

Bristol-Myers Squibb logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Its small molecule drugs are administered orally in the form of a pill or tablet. Its biologics are administered to patients through injections or by infusion. It offers products in a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: BMY
  • CUSIP: 11012210
Key Metrics:
  • Previous Close: $58.76
  • 50 Day Moving Average: $69.06
  • 200 Day Moving Average: $68.34
  • Trailing P/E Ratio: 34.36
  • Foreward P/E Ratio: 19.39
  • P/E Growth: 1.14
  • Market Cap: $98.18B
  • Outstanding Shares: 1,670,858,000
  • Beta: 0.52
Additional Links:
Companies Related to Bristol-Myers Squibb:

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb (NYSE:BMY) (?)
Ratings Breakdown: 2 Sell Ratings, 11 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $71.00 (20.83% upside)

Analysts' Ratings History for Bristol-Myers Squibb (NYSE:BMY)
DateFirmActionRatingPrice TargetDetails
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldView Rating Details
8/15/2016Credit Suisse Group AGReiterated RatingHold$63.00View Rating Details
8/13/2016ArgusReiterated RatingBuy$90.00View Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00View Rating Details
8/10/2016William BlairReiterated RatingBuyView Rating Details
8/9/2016Citigroup Inc.Lower Price TargetBuy$80.00 -> $75.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$69.00 -> $65.00View Rating Details
8/8/2016Deutsche Bank AGLower Price TargetHold$68.00 -> $62.00View Rating Details
8/8/2016Jefferies GroupLower Price TargetHold$80.00 -> $69.00View Rating Details
8/5/2016SunTrust Banks Inc.DowngradeBuy -> Neutral$86.00 -> $68.00View Rating Details
7/29/2016Leerink SwannReiterated RatingBuy$85.00View Rating Details
7/6/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
5/23/2016Hilliard LyonsInitiated CoverageNeutralView Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
4/29/2016Barclays PLCBoost Price TargetEqual Weight$70.00 -> $75.00View Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00View Rating Details
1/25/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$74.00 -> $70.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00View Rating Details
12/14/2015Cowen and CompanyReiterated RatingOutperform$75.00 -> $100.00View Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00View Rating Details
11/28/2014FBR & CoReiterated RatingPositiveView Rating Details
10/27/2014MKM PartnersBoost Price TargetSell$34.00 -> $36.00View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Bristol-Myers Squibb (NYSE:BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216$0.66$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.41$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb (NYSE:BMY)
Current Year EPS Consensus Estimate: $2.63 EPS
Next Year EPS Consensus Estimate: $3.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.63$0.66$0.64
Q2 20164$0.65$0.69$0.67
Q3 20163$0.61$0.66$0.64
Q4 20163$0.57$0.61$0.59
Q1 20171$0.74$0.74$0.74
Q2 20171$0.80$0.80$0.80
Q3 20171$0.84$0.84$0.84
Q4 20171$0.86$0.86$0.86
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb (NYSE:BMY)
Annual Dividend:$1.52
Dividend Yield:2.59%
Payout Ratio:87.36% (Based on Trailing 12 Months of Earnings)
57.79% (Based on Current Year Consensus EPS Estimate)
50.17% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.90% (3 Year Average)

Dividend History for Bristol-Myers Squibb (NYSE:BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Bristol-Myers Squibb (NYSE:BMY)
DateHeadline logoShort Interest Decreases By 31.4% For BMY (NYSE:BMY) - August 25 at 3:13 PM
News IconBristol-Myers Squibb Company (NYSE:BMY) from Drug Manufacturers – Major – Todays Top Gains (NYSE:BMY) - August 25 at 8:46 AM logoInvestigation for Investors in Bristol-Myers Squibb Co (NYSE:BMY) over Potential Wrongdoing Announced (NYSE:BMY) - August 24 at 3:52 PM
News IconWorth Watching Stocks: Bristol-Myers Squibb Co (NYSE:BMY), Nokia Corp (ADR) (NYSE:NOK) - NYSE Journal (press release) (NYSE:BMY) - August 24 at 12:07 PM
News IconBristol-Myers Squibb Co (NYSE:BMY): Price Reaction History - Post Registrar (NYSE:BMY) - August 24 at 12:07 PM logoHow Did Bristol-Myers Squibb Fare in 2Q16? (NYSE:BMY) - August 24 at 12:07 PM logoBristol-Myers Squibb (BMY), Pfizer (PFE) Will Present New Eliquis Data at ESC Congress 2016 - (NYSE:BMY) - August 23 at 8:02 AM logoCan Bristol-Myers Squibb Co's (BMY) Eliquis Rule the Cardiovascular Segment? - TCC (NYSE:BMY) - August 23 at 8:02 AM logoBristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 (NYSE:BMY) - August 23 at 8:02 AM logoCan Bristol-Myers Squibb Co's (BMY) Eliquis Rule the Cardiovascular Segment? (NYSE:BMY) - August 22 at 3:57 PM logo5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan (NYSE:BMY) - August 21 at 3:46 PM logoBristol Myers Squibb : Fukoku Mutual Life Insurance Co Lowers stake in Bristol-Myers Squibb Co (BMY) (NYSE:BMY) - August 21 at 8:35 AM logoThese 3 Stocks Could Boost Their Dividends in the Next 12 Months (NYSE:BMY) - August 20 at 8:53 AM
News IconDrug Manufacturers – Major: Bristol-Myers Squibb Company (NYSE:BMY) Position of the day (NYSE:BMY) - August 19 at 4:36 PM
News IconMost Active Performers for the Day- Nuveen California Dividend Advantage Municipal Fund 2 (NYSE:NVX), Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - August 19 at 12:14 PM logoProfit From Bristol-Myers' Drug Failure And Increased Volatility (NYSE:BMY) - August 19 at 12:14 PM
News IconAnalysts Valuations For Two Stocks: Bristol-Myers Squibb Co (NYSE:BMY), Incyte Corporation (NASDAQ:INCY) - The Voice Registrar (NYSE:BMY) - August 18 at 4:01 PM
News IconBristol-Myers Squibb Co.: If This Happens, BMY Stock Could Crash - Profit Confidential (NYSE:BMY) - August 18 at 4:01 PM
News IconBristol-Myers Squibb Co.: If This Happens, BMY Stock Could Crash (NYSE:BMY) - August 18 at 12:18 PM
News IconTop Gainers of the Day: Bristol-Myers Squibb Company (NYSE:BMY) from Drug Manufacturers – Major (NYSE:BMY) - August 17 at 12:11 PM logoBristol-Myers Squibb attracts upside bets (NYSE:BMY) - August 17 at 12:10 PM logoCan Bristol-Myers Squibb Company (BMY) Survive Opdivo Failure? - TCC (NYSE:BMY) - August 16 at 9:13 PM
News IconBristol-Myers Squibb Co. (NYSE: BMY) stock rating reiterated at Credit Suisse Group AG - BNB Daily (blog) (NYSE:BMY) - August 16 at 9:13 PM logoNoteworthy Tuesday Option Activity: BMY, ELLI, GNC (NYSE:BMY) - August 16 at 4:04 PM logoMirror Image: Bristol-Myers Loss Is Merck's Potential Gain (NYSE:BMY) - August 16 at 12:36 PM logoCan Bristol-Myers Squibb Company (BMY) Survive Opdivo Failure? (NYSE:BMY) - August 16 at 12:36 PM
News IconLeading stocks in today’s market: Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - August 15 at 4:00 PM logoBristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist (NYSE:BMY) - August 15 at 4:00 PM logoBristol-Myers Squibb Company Co (BMY) Investment Increased by Polar Capital Llp (NYSE:BMY) - August 15 at 11:06 AM logoBavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study (NYSE:BMY) - August 15 at 11:06 AM logoBristol-Myers to Reacquire Rights to Oncology Drug in Asia (NYSE:BMY) - August 15 at 11:06 AM logoBristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow (NYSE:BMY) - August 14 at 3:36 PM
News IconBristol Myers Squibb Middle East Dubai (NYSE:BMY) - August 14 at 8:42 AM logo3 Beaten-Up Big Pharma Stocks: Are They Bargains? (NYSE:BMY) - August 14 at 8:42 AM
News IconUpdate on Bristol-Myers Squibb Company (NYSE:BMY) for the day (NYSE:BMY) - August 13 at 3:53 PM
News IconJennison Associates buys $2099197672 stake in Bristol-Myers Squibb Co (BMY) (NYSE:BMY) - August 13 at 3:53 PM logoStrategy To YieldBoost Bristol-Myers Squibb Co. To 6.2% Using Options - Nasdaq (NYSE:BMY) - August 12 at 8:43 PM logoBristol Myers: Science Trumps The Headlines - Seeking Alpha (NYSE:BMY) - August 12 at 3:23 PM logoBristol-Myers Squibb Company Co (BMY) Position Increased by Mitsubishi Ufj Trust & Banking Corp - Finance Daily (NYSE:BMY) - August 12 at 12:31 PM logoBristol-Myers Squibb Co (BMY) Downgraded by Berenberg Following CheckMate-026 Miss (NYSE:BMY) - August 11 at 3:57 PM logoBerenberg Downgrades Bristol-Myers Squibb Co. (BMY) to Hold (NYSE:BMY) - August 11 at 3:57 PM logoWill Bristol-Myers (BMY) Stock Be Hurt by Downgrade? (NYSE:BMY) - August 11 at 3:57 PM
News IconIs Pharmaceutical Giant Bristol-Myers Squibb (BMY) a Buy? (NYSE:BMY) - August 11 at 12:02 PM
News IconIs Bristol-Myers Squibb Company (NYSE:BMY), a large market cap stock a smart buy? (NYSE:BMY) - August 11 at 12:02 PM logoBristol-Myers downgraded by Berenberg (NYSE:BMY) - August 11 at 12:02 PM logoCramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal (NYSE:BMY) - August 11 at 12:02 PM logoBerenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside (NYSE:BMY) - August 11 at 12:02 PM logoThe Market In 5 Minutes: Valeant's Fraud, Macy's Beat, And Arianna's Departure (NYSE:BMY) - August 11 at 12:02 PM logoThe Bristol-Myers Squibb Drug Bust (NYSE:BMY) - August 10 at 9:21 PM logoAfter Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers? (NYSE:BMY) - August 10 at 9:21 PM


Bristol-Myers Squibb (NYSE:BMY) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff